Abbott Concludes Former Employees’ Allegations Concerning Michigan Formula Plant ‘Unfounded’

Firm Plans Spending $500M To Build US Facility To Boost Formula Production

Abbott’s Q3 worldwide sales of formula and other pediatric nutritionals were down 24.8% on reported basis. It plans spending $500m on a new formula facility after finding the US “would benefit from more manufacturing capacity and redundancy.”

• Source: Shutterstock

Abbott is done investigating a former employee’s allegations about quality-control problems at its Michigan infant formula plant but impacts on revenues from temporarily shutting down the facility aren’t done with the firm.

Another impact from the shutdown and Abbott’s related recall of three of its major formula brands the firm announced with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Reckitt Leans On Europe As It Resets Mucinex In US

 
• By 

Decision to reformulate Mucinex sinus products without phenylephrine hits Reckitt's Q2 sales but the firm says it is preparing for upcoming cold & flu season with new marketing push.

Nestlé Puts VMS Value Brands On Chopping Block To Focus On Premium Market

 
• By 

Nature’s Bounty, Osteo Bi-Flex and Puritan’s Pride are among the dietary supplement brands under strategic review by Nestle as the firm shifts its focus to the premium end of the market.

BioGaia Takes Probiotics To Netherlands For First Time

 
• By 

Adopting an online approach, BioGaia is set to enter the Dutch market for probiotic dietary supplements. The firm announced the move as it reported lower sales in Q1.

IQVIA Consumer Health: Digestive Category Driving Global OTC Market Growth

 
• By 

An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.

More from Business

Vision Healthcare Strikes Deals To Expand European Offering

 
• By 

Belgium-based Vision Healthcare has acquired Svenskt Kosttillskott in Sweden and New Care Supplements in the Netherlands.

Over The Counter: Seizing The GLP-1 Wellness Opportunity, With Kerry Group’s Mathieu Millette

 
• By 

HBW Insight speaks to Kerry Group's RDA director for digestive health, Mathieu Millette, about the opportunity represented by the global trend for GLP-1 agonists for consumer health.

Consumers More Often Choosing Private Label First

 

First Insight report from survey conducted in April with 1,267 US consumers notes that the Private Label Manufacturers Association recorded private label sales increasing by nearly 4% in 2024 to a record $271bn.